Science ❯Medical Science
Oncology Mergers and Acquisitions Cell Therapy Biotechnology Clinical Trials Patient Care Drug Development Cancer Research Corporate Strategy Medical Treatments
An Innosuisse grant will let PSI’s radiopharmaceutical scientists refine a CD30-targeted terbium-161 therapy before initial human trials.
